Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
9004-54-0
Molecular formula
Not available
Molecular weight
Not available
Drug class
Branched glucose polysaccharideplasma volume expander and pharmaceutical polymer
Mechanism of action
High-molecular-weight dextran acts as a colloid osmotic agent in the intravascular compartment, expanding plasma volume. Lower molecular-weight dextrans have additional effects on blood rheology and platelet/coagulation interactions.
Indications / reported uses
Historical use as an intravenous plasma volume expander in selected settings; use is restricted or uncommon due to anaphylaxis, renal and coagulation risks. Other dextran grades are used as excipients or in diagnostic products and should not be treated as therapeutic substitutes.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Dextran Environmental Risk Assessment (ERA) (the Dextran ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.